

# Ashkan A Shahbandi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9069411/publications.pdf>

Version: 2024-02-01

14  
papers

425  
citations

1477746

6  
h-index

1719596

7  
g-index

14  
all docs

14  
docs citations

14  
times ranked

745  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer. <i>Cell Death and Differentiation</i> , 2020, 27, 3097-3116.        | 5.0 | 70        |
| 2  | TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines. <i>Trends in Cancer</i> , 2020, 6, 98-110.  | 3.8 | 81        |
| 3  | Medical students's ability to diagnose common dermatologic conditions in skin of color. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 957-958.                                | 0.6 | 53        |
| 4  | Analysis of race and gender disparities in incidence-based mortality in patients diagnosed with thyroid cancer from 2000 to 2014.. <i>Journal of Clinical Oncology</i> , 2020, 38, e18570-e18570. | 0.8 | 0         |
| 5  | Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival. <i>Journal of Cell Biology</i> , 2019, 218, 3827-3844.  | 2.3 | 80        |
| 6  | Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activity. <i>Npj Precision Oncology</i> , 2019, 3, 1.  | 2.3 | 73        |
| 7  | Nation-wide trends in mortality of patients with ocular and orbit melanoma: 2000 to 2014.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21061-e21061.   | 0.8 | 0         |
| 8  | Receptor Regulation in Taste: Can Diet Influence How We Perceive Foods?. <i>J</i> , 2018, 1, 106-115.   | 0.6 | 5         |
| 9  | Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment. <i>Breast Cancer Research</i> , 2018, 20, 115.  | 2.2 | 63        |
| 10 | cfDNA analysis of mCRPC patients expressing mutations in Wnt signaling.. <i>Journal of Clinical Oncology</i> , 2018, 36, 256-256.   | 0.8 | 0         |
| 11 | cfDNA TP53 mutations with treatment history and disease progression in metastatic CRPC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 263-263.   | 0.8 | 0         |
| 12 | Cosegregation of cfDNA AR amplifications and mutations in relation to BRAF and MYC in CRPC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 261-261.   | 0.8 | 0         |
| 13 | Cell-free DNA (cfDNA) analysis and evaluation of BRAF amplifications and mutations in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 255-255.  | 0.8 | 0         |
| 14 | Abstract 3830: Novel small molecule translation inhibitors with safety and efficacy in triple negative breast cancer (TNBC) animal models. , 2012, , .  |     | 0         |